Curis Hedgehog and Beyond --plus multi-targeting cancer inhibitors

The emergence of new small molecules with capacity of blocking the Hedgehog signaling pathway provides a novel therapeutic approach in pancreatic adenocarcinoma treating the primary tumor, stroma, systemic metastases and pancreatic cancer stem cells by hedgehog pathway inhibition. This phase 2 clinical trial will evaluate the progression free survival (PFS) in patients with previously untreated metastatic pancreatic adenocarcinoma. We hypothesize that the combination of cytotoxic agents (gemcitabine and nab-paclitaxel) with the Hedgehog inhibitor GDC-0449 may ...

http://clinicaltrials.gov/ct2/show/NCT01071564

The Notch like the Hedgehog pathway is very important in stem cell maintenance and repair of cells. This is also a Roche Compound.

http://www.cnb.uam.es/~jlpompa/


The second is a blocker of Hh (hedgehog) signaling, GDC-0449, which we are combining with a blocker of gamma secretase (RO4929097) in a novel study for people with recurrent sarcomas. We are seeking funding to perform this multi-center study, focusing on biopsies ...

http://clinicaltrials.gov/ct2/show/NCT01064622
Gemcitabine Hydrochloride With or Without GDC-0449 in Treating Patients With Recurrent or Metastatic Pancreatic Cancer
Purpose
RATIONALE: Drugs used in chemotherapy, such as gemcitabine hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. GDC-0449 may slow the growth of tumor cells. It is not yet known whether giving gemcitabine hydrochloride together with GDC-0449 is ...

Advanced Solid Tumors
http://clinicaltrials.gov/ct2/show/NCT00880308?term=LDE225 PI
This first-in-human dose-escalation study is to characterize the safety, tolerability, pharmacokinetics and pharmacodynamics of LDE225 given orally on a daily dosing schedule in patients with advanced solid tumors.
Study Start Date: March 2009
Estimated Primary Completion Date: December 2010

Skin Basal Cell Carcinomas in Gorlin's Syndrome Patients PI / PII
http://clinicaltrials.gov/ct2/show/NCT00961896?term=LDE225
A double-blind, randomized, vehicle-controlled Proof of Concept (PoC) study to evaluate the safety, local tolerability, pharmacokinetics and pharmacodynamics of ...

Advanced and/or Metastatic Solid Tumor Malignancies PI
http://clinicaltrials.gov/ct2/show/NCT00761696?term=IPI-926
A Phase 1 Study of IPI-926 in Patients With Advanced and/or Metastatic Solid Tumor Malignancies

http://clinicaltrials.gov/ct2/results?term=IPI-926

First Line Colon Cancer

Completed Enrollment Q2 2009 N=199

Advanced Ovarian Cancer

Completed Enrollment Q4 2009 N=104

Advanced BCC

FPI Q1 2009 N=100

Hedgehog Inhibition for Pancreatic Ductal Adenocarcinoma (PDAC) in the Preoperative Setting (HIPPoS)

http://www.clinicaltrials.gov/ct2/show/NCT01096732?term=GDC-0449
Purpose
This clinical trial is looking at the effect of a new drug called GDC-0449 in patients with cancer of the pancreas. Laboratory studies have shown that this drug blocks a process in pancreatic cells thought to be involved in cancer development and spread. This process is called the 'Hedgehog signalling pathway'. As yet, it is unclear whether blocking hedgehog signalling will ...

Chronic Myeloid Leukemia (CML) Phase I
http://clinicaltrials.gov/ct2/show/NCT00953758?term=PF-04449913
This study examines the effect of a small molecule inhibitor to the Sonic Hedgehog pathway on select hematologic malignancies. Part two of the study will examine the effect of this inhibitor in combination with dasatinib.

Study Start Date: January 2010
Estimated Study Completion Date: April 2013


http://clinicaltrials.gov/ct2/results?term=PF-04449913

Extensive-Stage Small Cell Lung Cancer Phase I
http://clinicaltrials.gov/ct2/show/NCT00927875?term=BMS-83392
The purpose of this study is to determine the maximum tolerated dose (MTD) of BMS-833923 administered in combination with carboplatin and etoposide followed by BMS-833923 alone in subjects with extensive-stage Small Cell Lung Cancer (SCLC).

Study Start Date: December 2009
Estimated Study Completion Date: July 2011

Metastatic Gastric, Gastroesophageal, or Esophageal Adenocarcinomas Phase I
http://clinicaltrials.gov/ct2/show/NCT00909402?term=BMS-833923
The purpose of this study is to determine the maximum tolerated dose ...